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INTRODUCTION
Colorectal poorly-differentiated (POR) neuroen-
docrine cell (NEC) carcinomas are rare aggressive
neoplasm at this location, accounting for less than
1 percent of all colorectal malignant tumors (1-7).
Furthermore, colorectal POR NEC carcinomas have
very poor prognosis, and treatments of this carci-
nomas are very difficult (1-7). We herein report a
coexistent POR NEC carcinoma and non-invasive
well-differentiated (WELL) adenocarcinoma in vil-
lous adenoma of the rectum.
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CASE REPORT
A 74-years old man was admitted to our hospital
in March 2009 after detection of a rectal mass dur-
ing investigation for difficult defecation and diarrhea.
Laboratory findings showed no abnormalities on
peripheral blood and serum examination. Colono-
scopy revealed villous tumor covering all the lower
rectal lumen 4 cm from anal verge (Fig. 1). Biopsy
yielded a diagnosis of adenoma. Abdominal com-
puted tomography (CT) showed the low density tu-
mor shadows of the rectum and the right hepatic
lobe (Fig. 2). Pelvic magnetic resonance imaging
on the T2 weighted images showed a large tumor
with slight high signal intensity of 10.587 cm in
the rectum (Fig. 3).
From the above findings, rectal cancer was con-
sidered most. Following a diagnosis of rectal cancer
that metastasized to the liver, lapalotomy was per-
formed. There were widespread liver metastasis and
lymphadenopathy in the abdomen. No peritoneal
dissemination was observed. Rectosigmoid resection
with lymph node dissection and total mesorectal
excision was performed. The resected specimens
showed elevated villous tumor covering all the rectal
lumen measuring 10.58 cm, in association with a
type 2 tumor in the anterior side (Fig. 4). Histo-
logical features showed two different components.
The elevated lesion consisted mainly of tubulovil-
lous adenoma containing WELL adenocarcinoma
confined to the mucosa (Fig. 5a). No conventional
adenocarcinoma cells were observed into the sub-
mucosa, the muscularis propria or the subserosa.
Whereas, the other type 2 tumor composed highly
atypical small cells with hyperchromatic nuclei and
scanty cytoplasm, in solid nests and trabeculae, re-
sembling the features of small cell carcinoma of the
lung. These small cells diffusely infiltrated the sub-
mucosa, the muscularis propria, the subserosa and
the serosa. Nuclei were irregular in size and mitotic
figures were frequently identified (Fig. 5b). Focal
necroses were found. Severe lymphatic and vascu-
lar invasions, as well as lymph node metastasis,
were observed. The type 2 small cell tumor was di-
agnosed pathologically as POR NEC carcinoma by
immunohistochemical study using Chromogranin
Fig. 1 : Colonoscopy revealed villous tumor covering all the
lower rectal lumen 4 cm from anal verge.
a b
Fig. 2 : Abdominal computed tomography showed the low density tumor shadows of the rectum and the right hepatic lobe.
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A (Chr A) (Fig. 6a) and Synaptophysin (Fig. 6b).
No immunoreactivity with LCA, CD3 or CD20 was
seen. No transitional zone was observed between
the adenocarcinoma in adenoma and the NEC car-
cinoma.
CT scan was performed 1 month after operation
and made clear an increasing metastases focus in
the liver (Fig. 7). The patient was given intravenous
combination chemotherapy using Fluorouracil, Fo-
linic acid, Oxaliplatin (FOLFOX) and Bevacizumab
postoperatively. But his general condition turned
worse by exacerbation of the cancer, he died in can-
cer 3 months after surgery.
Fig. 3 : Pelvic magnetic resonance imaging on the T2 weighted images showed a large tumor with slight high signal intensity of
10.587 cm in the rectum.
Fig. 4 : The resected specimens showed elevated villous tu-
mor covering all the lower rectal lumen measuring 10.58 cm,
in association with type 2 tumor in the anterior side.
a b
Fig. 5 : Histological features showed two different components. The elevated lesion consisted mainly of tublovillous adenoma con-
taining well -differentiated adenocarcinoma confined to the mucosa (Fig. 5a)(H.E.100). Nuclei of the NEC carcinoma cells were ir-
regular in size and mitotic figures were frequently identified. Focal necroses were found (Fig. 5b) (H.E.200).
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DISCUSSION
The classification of gastrointestinal (GI) NEC
tumors is controversial. The chapter of GI NEC tu-
mors was deleted from latest World Health Organi-
zation (WHO) classification of the tumors of endo-
crine organs (8). Therefore, GI NEC carcinomas are
classified in accordance with WHO classification of
the tumors of the digestive system (9). However, it
is thought that three following subgroups are easy
to grasp the property of GI NEC tumors. In other
words it is 1) WELL NEC tumors of benign or un-
certain behavior, 2) WELL NEC carcinomas of low
grade malignancy, so-called carcinoid tumor and
3) POR or undifferentiated NEC carcinomas of high
grade malignancy. Furthermore, a dichotomous
classification scheme, small cell vs. non-small cell
including large cell, for POR NEC carcinomas of
the GI tract has been present (10). Hence, our NEC
tumor case is thought to be classified in POR small
cell NEC carcinoma.
Colorectal POR NEC carcinomas are uncommon,
comprising less than 1 percent of all colorectal ma-
lignancies. The first described series of colorectal
small cell NEC carcinoma was reported in 1978
(11). In Japan, the first documented series of rec-
tal POR NEC carcinoma was reported in 1984 (1).
Since that initial Japanese description, a total 48
cases of rectal POR NEC carcinomas have been re-
ported in Japan (12-15). Colorectal POR NEC car-
cinomas are sometimes associated with adenoma
and/or adenocarcinoma (16, 17). Coexistent NEC
carcinoma and adenocarcinoma is so-called ade-
noendocrine cell carcinoma. In Japan, there were
20 isolated reports describing rectal adenoendo-
crine cell carcinoma including our case (Table 1).
a b
Fig. 6 : Immunohistochemical features. The NEC carcinoma cells are immunoreactive for (a) Chr A (200) and (b) SNP (200).
Fig. 7 : CT scan performed 1 month after operation found an increasing metastases focus in the liver.
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In our case, the NEC carcinoma was next to the
non-invasive WELL adenocarcinoma in tubulovillous
adenoma. The adenocarcinoma in adenoma located
upper layer confined to the mucosa. On the other
hand, the NEC carcinoma located lower layer. Each
tumor of the adenocarcinoma in adenoma and the
NEC carcinoma were two-tiered structure. The his-
togenesis of tumors containing both glandular and
endocrine components is not fully elucidated. But
according to the current histological and molecu-
lar studies, it has been considered that both NEC
carcinoma and adenocarcinoma are derived from a
multi-potential stem cell (18-21). Our case seems
consistent with this theory by morphological feature.
Colorectal POR NEC carcinomas have very poor
prognosis. The negative prognostic factors of gastro-
enteropancreatic NEC tumors such as expression of
Chr A, high Ki-67 indexes, high mitotic rates, large
size of the primary tumor and presence of metasta-
sis have made clear (7, 22, 23). Our case had four
negative prognostic factors mentioned above. A
novel TNM classification including a Ki-67 index
or mitotic index based grading system has been ad-
vocated by the European Neuroendocrine Tumor
Society (ENTS) (24). According to this ENTS TNM
classification, clinical stage of our case was T4 (in-
vasion to the seminal vesicle and prostate), N1, M1
(liver), stage4. Whereas a new TNM classification,
7th edition has been published by International
Union Against Cancer (UICC) (25). The GI NEC
tumor is expressed as a new classification by this
UICC TNM classification. However, the UICC TNM
classification of the GI NEC tumors is only carci-
noids. POR NEC carcinoma must be classified as
GI carcinoma of small cell/large cell. So, clinical
stage of our case was T4b (invasion to the seminal
vesicle and prostate), N2b, M1a (liver), stage4A in
accordance with update UICC TNM classification,
7th edition.
The medical treatment against colorectal POR
NEC carcinomas is controversial. ENTS’s Guide-
lines for the management of patient with colorectal
NEC tumors recommend systemic chemotherapy
using cisplatin/etoposide (26, 27). In Japan, the ef-
fective case with chemotherapy that used cisplatin/
irinotecan against the rectal POR NEC cancer has
been reported (28). In ASCO 2006, the outcome
that the FOLFOX-4 regimen was well tolerated and
effective in progressive malignant NEC carcinoma
with increased proliferative potential was presented
(29). Although there are some optional chemother-
apy regimens for the advanced colorectal POR NEC
carcimona, few prospective randomized chemother-
apy studies is still being performed. For our case,
we used FOLOX-6 and Bevacizumab being the
drugs of choice currently prescribed for colorectal
adenocarcinomas. The initial chemotherapy was
done. But the general condition of the patient be-
came worse because of increased liver metastases.
The continuation of the chemotherapy became dif-
ficult. So, this resume was not able to be evaluated.
In conclusion, surgical resection and adjuvant
chemotherapy will be necessary as main treatment
of the colorectal POR NEC carcinoma. Effective
multimodal therapy for NEC carcinoma should be
established.
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